Researchers are developing new osteoporosis treatment
Endocrinologists at the University of Pittsburgh (UP) are in the process of developing a treatment of osteoporosis using a naturally occurring hormone that promises to strengthen weakened bones, according to The Brilliant Stories.
The treatment, known as parathyroid hormone-related protein (PTHrP), is about to enter into the testing stage. The chief researcher in the trial, Dr Mara J. Horwitz, ascertained that test subjects would be randomly prescribed to take PTHrP or teriparatide, which causes some bone breakdown, but builds bone density.
PTHrP was developed by Dr Andrew F. Stewart, who is the chief of the Division of Endocrinology and Metabolism in UP's School of Medicine. Researchers are seeking to find out if the hormone can be used in the treatment of osteoporosis with minimal side effects, the news source reports. A metabolic bone specialist at UP, Dr Horwitz said that since it is an anabolic agent and promotes bone formation without any breakdown, it is promising.
Approximately 8 million women and 2 million men have osteoporosis in the U.S., according to the National Osteoporosis Foundation.